Sofosbuvir/daclatasvir

From Wikipedia, the free encyclopedia
Sofosbuvir/daclatasvir
Sovodak.jpg
Sovodak 60/400
Combination of
DaclatasvirNS5A inhibitor
SofosbuvirNS5B (RNA polymerase) inhibitor
Clinical data
Trade namesDarvoni,[1] Sovodak
Routes of
administration		Oral
Identifiers
CAS Number
  • 2306918-02-3

Daclatasvir/sofosbuvir is a two-drug combination for the treatment of hepatitis C.[2] It is given as a single daily pill containing daclatasvir, the viral NS5A inhibitor and sofosbuvir, a nucleotide inhibitor of the viral RNA polymerase.[medical citation needed]

Society and culture[]

This combination is produced by an Iranian company under the trade name of Sovodak.[3] The combination includes 400 mg sofosbuvir and 60 mg daclatasvir and has been used in clinical trials since 2015.[4][5][6] Sovodak was approved by the Iranian Food and Drug Administration in October 2015[7] and is currently marketed in Iran as the treatment of choice for all genotypes of hepatitis C as recommended by the national Iranian guideline for treating hepatitis C.[8]

Research[]

The similarities between the hepatitis C and SARS-CoV-2 virus has led some researches to investigate the effectiveness of sofosbuvir/daclatasvir against COVID-19. Three recently published studies have found this combination to be beneficial against COVID-19 although the findings require confirmation by larger studies.[9][10][11]

References[]

  1. ^ "Home". Darvoni - Beacon Medicare Limited.
  2. ^ Pol S, Corouge M, Vallet-Pichard A (2016). "Daclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life". Hepatic Medicine: Evidence and Research. 8: 21–6. doi:10.2147/HMER.S62014. PMC 4786064. PMID 27019602.
  3. ^ Codrops. "Sovodak دارو". Retrieved 2019-07-17.
  4. ^ https://clinicaltrials.gov/ct2/show/NCT02596880?term=sovodak&rank=1
  5. ^ Merat, Shahin; SD1000 Research Team (2020). "SD1000: High Sustained Viral Response Rate in 1361 Patients with Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial". Clinical Infectious Diseases. 70 (10): 2206–2212. doi:10.1093/cid/ciz628. PMID 31504303.
  6. ^ Poustchi, Hossein; Majd Jabbari, Sara; Merat, Shahin; et al. (2020). "The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment". Journal of Gastroenterology and Hepatology. 35 (9): 1590–1594. doi:10.1111/jgh.14994. PMID 31994788.
  7. ^ http://fda.gov.ir/uploads/05d8977da309fd47b21defea18d027ed.xls
  8. ^ "Hepatitis Monthly | International Monthly Journal in the Field of Hepatology". Hepatitis Monthly. Retrieved 2019-07-17.
  9. ^ Eslami, Gholamali; Mousaviasl, Sajedeh; Radmanesh, Esmat; et al. (2020). "The impact of sofosbuvir/Daclatasvir or ribavirin in patients with severe COVID-19". Journal of Antimicrobial Chemotherapy. 75 (11): 3366–3372. doi:10.1093/jac/dkaa331. PMC 7529105. PMID 32812051. S2CID 221182215.
  10. ^ Sadeghi, Anahita; Ali Asgari, Ali; Norouzi, Alireza; et al. (2020). "Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): A randomized controlled trial". Journal of Antimicrobial Chemotherapy. 75 (11): 3379–3385. doi:10.1093/jac/dkaa334. PMC 7454592. PMID 32812039. S2CID 221181054.
  11. ^ Abbaspour Kasgari, Hamideh; Moradi, Siavash; Shabani, Amir Mohammad; et al. (2020). "Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: A single-centre, randomized controlled trial". Journal of Antimicrobial Chemotherapy. 75 (11): 3373–3378. doi:10.1093/jac/dkaa332. PMC 7454669. PMID 32812025. S2CID 221180153.


Stub icon

This antiinfective drug article is a stub. You can help Wikipedia by .

  • v
  • t
Retrieved from ""